Jomaa Pharma GmbH

Quick facts

Phase 2 pipeline

• Fosmidomycin and Clindamycin co-administration · Infectious Diseases
  Fosmidomycin inhibits the enzyme 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), which is involved in the biosynthesis of isoprenoids, while clindamycin inhibits protein synthesis by binding to the 50S ribosomal subunit.
• Fosmidomycin-Piperaquine

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Jomaa Pharma GmbH portfolio CI brief
• Jomaa Pharma GmbH pipeline updates RSS